Portal de Periódicos da CAPES

Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial

2024; Elsevier BV; Volume: 24; Issue: 11 Linguagem: Inglês

10.1016/s1473-3099(24)00358-x

1474-4457

Glenda Gray, Kathryn Mngadi, Ludo Lavreys, Steven Nijs, Peter B. Gilbert, John Hural, Ollivier Hyrien, Michal Juraska, Alex Luedtke, Philipp Mann, M. Juliana McElrath, Jackline Odhiambo, Daniel J. Stieh, Janine van Duijn, Azwidihwi Takalani, Wouter F. Willems, Asa Tapley, Georgia D. Tomaras, Johan Van Hoof, Hanneke Schuitemaker, Edith Swann, Dan H. Barouch, James G. Kublin, Lawrence Corey, Maria Grazia Pau, Susan Buchbinder, Frank Tomaka, Jon J. Allagappen, Jessica Andriesen, Alison Ayres, Linda‐Gail Bekker, Caroline Borremans, William Brumskine, Roma Chilengi, Thozama Dubula, Nigel Garrett, Huub C. Gelderblom, Katherine Gill, Zaheer Hoosain, Mina C. Hosseinipour, Julia Hütter, Mubiana Inambao, Craig Innes, William Kilembe, Philippus Kotze, Sheena Kotze, Fatima Laher, László Imre, Erica Lazarus, Mookho Malahleha, Matsontso Mathebula, Mitch Matoga, Rachael McClennen, Pamela Mda, Peter Meerts, Vimla Naicker, Logashvari Naidoo, Tricia Philip, Annah Pitsi, Lorenz Scheppler, Carrie Sopher, Simbarashe Takuva, Edna Viegas, Mo Weijtens, Olive Yuan,

Adolescent Sexual and Reproductive Health

HIV type 1 (HIV-1) remains a global health concern, with the greatest burden in sub-Saharan Africa. Despite 40 years of research, no vaccine candidate has shown durable and protective efficacy against HIV-1 acquisition. Although pre-exposure prophylaxis in groups with high vulnerability can be very effective, barriers to its use, such as perceived low acquisition risk, fear of stigma, and concerns about side-effects, remain. Thus, a population-based approach, such as an HIV-1 vaccine, is needed. The current study aimed to evaluate the efficacy and safety of a heterologous HIV-1 vaccine regimen, consisting of a tetravalent mosaic adenovirus 26-based vaccine (Ad26.Mos4.HIV) and aluminium phosphate-adjuvanted clade C glycoprotein (gp) 140, in young women at risk of acquiring HIV-1 in southern Africa.